Respiratory Distress Syndrome Management Market Snapshot (2023 to 2033)
The global respiratory distress syndrome management market is slated to reach a valuation of US$ 115.4 billion in 2023. According to Future Market Insights, the market is expected to grow at a 4.41% CAGR until 2033, valued at US$ 177.7 billion. Also, according to the recent study by FMI, it is noted that the industry sponsors will be leading the market with an expected share of about 54.7% in the year 2023, within the global market.
Several factors that can drive the market growth such as improved healthcare facilities with an increase in research and drug development for the treatment, technological advancements in the treatment & increase in healthcare investment day by day will lead to profitable growth opportunities in the forecast period.
This global respiratory distress syndrome treatment is a serious life-threatening viral infection including symptoms like cough, chills and shaking, headache, etc is said to be transferrable from one person to another in a short period. In October 2012, this infection was added to National Select Agent Registry, regulating the handling and control of bacteria and virus that is said to cause severe risk to the public’s health and safety.
The development of the global respiratory distress syndrome treatment may be restrained due to a lack of qualified and experienced specialists who have no idea of the treatment available for this illness can restraint the growth of the market during the forecast period. Moreover, Limited approved drugs for the treatment also inhibited the growth of the market.
Antivirals and antibiotics are generally recommended for the treatment of this respiratory distress syndrome treatment. But in many cases, antibiotic treatment is alone not enough for the treatment, supportive care is also required.
Attributes
Details
Base year Market Value (2022)
US$ 110.3 billion
Projected Forecast Value (2023)
US$ 115.4 billion
Projected Forecast Value (2033)
US$ 177.7 billion
Growth rate
4.41%
Forecast period
2023 to 2033
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Respiratory Distress Syndrome Management Market Historical Period 2018 To 2022 Demand Analysis Vs. Forecast 2023
The global respiratory distress syndrome management market grew at a CAGR of 4.24% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
Historically, the focus of mechanical ventilation in respiratory failure has been to maintain adequate oxygenation and carbon dioxide elimination where several preclinical studies indicated that the common clinical practice of using relatively high tidal volumes and elevated airway pressures for ARDS patients might exacerbate the degree of lung injury.
In the year 2000, investigators supported by the US National Heart Lung and Blood Institute ARDS Network completed a randomized phase III clinical trial in which a tidal volume of 6 ml per kg PBW, compared with the more common higher tidal volume of 12 ml per kg PBW, improved survival, shortened duration of mechanical ventilation, attenuated systemic inflammation and accelerated recovery of extra-pulmonary organ failures, and the biologic findings were reported in other studies. Thus, with the discovery of the major role that mechanical forces play in the pathogenesis of lung injury, optimizing ventilator support to minimize VALI has become central to the clinical management of ARDS, leading to the concept of lung-protective ventilation.
The recently developed Radiographic Assessment of Lung Edema (RALE) score may be a novel tool to predict severity, outcomes, and response to therapy in ARDS. In the derivation cohort of this study, the RALE score was correlated with lung weight from excised lungs in deceased organ donors 3. Before the widespread use of this score, extensive validation is required. The use of lung ultrasound for the diagnosis of ARDS may be a promising tool but needs further study. Sensitive and specific biomarkers of ARDS, if available, may aid in earlier and more accurate diagnosis. Also, Future investigations should refine clinical, radiographic, physiological, molecular, and genetic differences in phenotypes to better understand the pathobiology of ARDS and develop novel therapies.
The rising incidence of clinical trials is driving growth
Increasing research and development and clinical trials and usage of therapeutics for the respiratory distress syndrome management market will eventually propel the growth of the market. Government initiatives taken to the reduction in mortality rate will also be a major factor that will help in the contribution of the growth of the market.
Increasing prevalence and incidence of acute lung injury
The increasing alcohol consumption, irrespective of age, leads to syndrome-like ARDS. Other risk factors like dyspnoea, hypertension, diabetes, and more lead to ARDS development. Thereby, this wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are anticipated to boost the growth of the market.
The rising rate of air pollution and lifestyle-related diseases
The World Health Organization, air pollution is one of the greatest environmental risks to health by increasing the burden of diseases like heart diseases and lung and respiratory infections at both acute and chronic levels. Hence, the rising air pollution rate in developed and developing countries increases the chances of people getting syndromes like acute respiratory distress syndrome. Thus, the factor is expected to drive the growth of the market.
Increasing accident rates and trauma causing ARDS
The inhalation of smoke releases materials like fibrin, neutrophils, mucus, and epithelial cell debris that occlude the airway lumen, causing changes in ventilation. This condition leads to hypoxemia which is a primary significant reason for ARDS. They also reported that increased mortality rates in burn patients were due to ARDS. Thereby, the rising number of accidents and trauma injuries in the lungs is expected to drive the growth of the market.
Find your sweet spots for generating winning opportunities in this market.
What Could Possibly Hinder Respiratory Distress Syndrome Management Market Demand?
Complications associated with treatments
There are treatments for ARDS helping people survive, but the complications associated with treatments and post-treatment are still a burden for patients. Most potential and lasting effects include breathing problems, depression, problems with memory and thinking, tiredness and muscle weakness, and more.
These complications associated with and post-treatment of acute respiratory distress syndrome are expected to hamper the market growth during our forecast period.
High cost of device and treatments
The high cost of ventilation treatment per day is not affordable if the therapy has to proceed for many days. Hence patients prefer taking ventilators for home care. However, the price of ventilators is yet quite expensive. Therefore, the high cost of treatment and ventilators is very challenging for people to afford any reliable remedy for the long term until the patient completely recovers. This is anticipated to hamper the growth of the market.
Region-wise Analysis
What Is the Outlook of The North American Respiratory Distress Syndrome Management Market Treatment?
The hospital segment in North America is expected to grow with the highest growth rate
The countries covered in the acute respiratory distress syndrome (ARDS) market report are USA., Canada, and Mexico. In the forecast period of 2023 to 2033 because of increasing government and organizational support.
The hospital segment in Canada is second dominating the market owing to increasing cases of chronic respiratory diseases and high adoption of proper diagnosis. Mexico is third leading the growth of the market and the hospital segment is dominating in this country due to the increasing number of new hospital infrastructures being opened due to the emergence of COVID-19.
Expectations from The Asia - Pacific Market for Respiratory Distress Syndrome Management Market Treatment?
Increasing technological advancement in the country
The parenteral segment in Japan is expected to grow with the highest growth rate in the forecast period of 2023 to 2033 because of increasing technological advancement in the country.
The parenteral segment in China is second dominating the market owing to increasing cases of chronic respiratory diseases and high adoption of proper diagnosis. South Korea is third leading the growth of the Asia-Pacific market and the parenteral segment is dominating in this country due to the increasing number of biotechnologies centers and research activities.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which Type of Respiratory Distress Syndrome Management Market Treatment is Most Prevalent?
The nasal segment will gain the dominant market share
Advancements in neonatal care have been driving growth as the survival rate of premature infants with RDS has increased due to improved diagnostic methods and treatments thus fuelling demand. Various leading companies like Smiths Medical offers neonatal care products, including neonatal ventilators and respiratory support devices.
Also, babies have survived longer and with less lung damage due to the introduction of volume-targeted ventilators as they require support for shorter periods leading to a low risk of developing pneumothorax.
Which distribution channel segment is expected to gain traction from 2023 to 2033?
The demand for hospital pharmacies will be more during the forecast period.
According to a report by Future Market Insights, the hospital pharmacies would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide market from 2023 to 2033.
Due to the rise in population and advancement in technologies, a growing number of people are more prone to visiting hospitals for advice on respiratory distress syndrome management market treatment-related, where they will be provided not only with proper care but also with the new and advanced level of instruments at each interval of time. As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.
Start-up Scenario
The start-ups in this sector aim to use several techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.
Hospitech Respiration- Israeli medical device start-up Hospitech Respiration was founded in 2006, and develops airway management solutions for mechanically-ventilated patients. Its AnapnoGuard system, in particular, has gained increased notoriety throughout 2020 due to the Covid-19 pandemic. The device provides automated control of the airway cuff pressure and automated evacuation of subglottic secretions in ventilated patients, preventing infection or damage in the lungs.
In November 2020, Hospitech Respiration also announced that, in response to increased global demand for its airway management system, it would be working with Chinese firm AwakeZone to open a new manufacturing facility in China, expanding production of the AnapnoGuard system in the country.
Aerin Medical- US health tech firm Aerin Medical develops therapeutic devices that improve nasal breathing by using low-power radiofrequency energy to remodel soft tissue in the nose. The two main procedures it offers via its proprietary Aerin technology are RhinAer, which provides lasting relief from chronic rhinitis – often characterized by a persistently runny nose – and VivAer, which is used to treat nasal obstruction.
Having been founded in 2011, Texas-headquartered Aerin Medical has also made major strides, appointing a new president and CEO – Matt Brokaw, formerly of Stryker and Johnson & Johnson – and raising US$ 48 million in funding in August 2020.
How Competitive is the Market for Respiratory Distress Syndrome Management Market Treatment?
Some of the prominent players in the global market for RDS treatment are
JW Pharmaceutical
Windtree Therapeutics, Inc.
ONY Biotech Inc
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
GlaxoSmithKline plc.
Pfizer Inc.
Gilead Sciences, Inc.
Hoffmann-La Roche Ltd
Fresenius Kabi AG
Some of the important developments of the key players in the market are
In May 2021, Medtronic announced the launch of the SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio.
In July 2020, F. Hoffman-La Roche Ltd announced the launch of the SARS-CoV-2 rapid antibody test. The test was launched in partnership with SD Biosenseor, Inc. This has helped the company to increase its product portfolio.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 4.41% from 2023 to 2033
Market value in 2023
US$ 115.4 Billion
Market value in 2033
US$ 177.7 Billion
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
USD Billion for Value and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug class
Route of Administration
End-user
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
United States
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC countries
South Africa
Israel
Key Companies Profiled
JW Pharmaceutical
Windtree Therapeutics, Inc.
ONY Biotech Inc
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
GlaxoSmithKline plc.
Pfizer Inc.
Gilead Sciences, Inc.
Hoffmann-La Roche Ltd
Fresenius Kabi AG
Customisation Scope
Available on Request
Key Segments Profiled in the Respiratory Distress Syndrome Management Market Report
Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Drug Class:
Vasoconstrictors
Bronchodilators
Steroids and Antibiotics
Route of administration:
Oral
Parenteral
Nasal
End User:
Hospital pharmacy
Online pharmacy
Retail pharmacy
Frequently Asked Questions
What is the Growth Potential of the Respiratory Distress Syndrome Management Market?
The growth potential of the market is 4.41% through 2033.
What Limits the Growth Potential of the Market?
Complication in treatment is likely to limit market growth.
What is Japan’s Expected Market Growth by 2033?
Rising technological advancements are fueling Japan’s growth by 2033.
What is the Current Market Valuation?
The market is estimated to get a valuation of US$ 115.4 billion in 2023.
Which Country is Set to Register Exponential Growth in the Respiratory Distress Syndrome Management Market?
Canada, the United States, and Japan may witness significant growth in the market.
Table of Content
1. Executive Summary | Respiratory Distress Syndrome Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global MarketAnalysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Vasoconstrictors
5.3.2. Bronchodilators
5.3.3. Steroids and Antibiotics
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Parenteral
6.3.3. Nasal
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033
7.3.1. Hospital pharmacy
7.3.2. Online pharmacy
7.3.3. Retail pharmacy
7.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033
8. Global MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By End-User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By End-User
9.4. Key Takeaways
10. Latin America MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By End-User
10.4. Key Takeaways
11. Europe MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By End-User
11.4. Key Takeaways
12. South Asia MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By End-User
12.4. Key Takeaways
13. East Asia MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By End-User
13.4. Key Takeaways
14. Oceania MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By End-User
14.4. Key Takeaways
15. MEA MarketAnalysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By Route of Administration
15.2.4. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By End-User
15.4. Key Takeaways
16. Key Countries MarketAnalysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By Route of Administration
16.1.2.3. By End-User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By Route of Administration
16.2.2.3. By End-User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By Route of Administration
16.3.2.3. By End-User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By Route of Administration
16.4.2.3. By End-User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By Route of Administration
16.5.2.3. By End-User
16.6. United kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By Route of Administration
16.6.2.3. By End-User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By Route of Administration
16.7.2.3. By End-User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By Route of Administration
16.8.2.3. By End-User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By Route of Administration
16.9.2.3. By End-User
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By Route of Administration
16.10.2.3. By End-User
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By Route of Administration
16.11.2.3. By End-User
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By Route of Administration
16.12.2.3. By End-User
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By Route of Administration
16.13.2.3. By End-User
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By Route of Administration
16.14.2.3. By End-User
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By Route of Administration
16.15.2.3. By End-User
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By Route of Administration
16.16.2.3. By End-User
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By Route of Administration
16.17.2.3. By End-User
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By Route of Administration
16.18.2.3. By End-User
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By Route of Administration
16.19.2.3. By End-User
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By Route of Administration
16.20.2.3. By End-User
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By Route of Administration
16.21.2.3. By End-User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By End-User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. JW Pharmaceutical
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Windtree Therapeutics, Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. ONY Biotech Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. AbbVie Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Teva Pharmaceutical Industries Ltd.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Takeda Pharmaceutical Company Limited
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. GlaxoSmithKline plc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Pfizer Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Gilead Sciences, Inc.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Hoffmann-La Roche Ltd
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Fresenius Kabi AG
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End-User, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Market Attractiveness by End-User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End-User, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Market Attractiveness by End-User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End-User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End-User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by End-User, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Market Attractiveness by End-User, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by End-User, 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 99: South Asia Market Attractiveness by End-User, 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by End-User, 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 119: East Asia Market Attractiveness by End-User, 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by End-User, 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033
Figure 139: Oceania Market Attractiveness by End-User, 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by End-User, 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033
Figure 159: MEA Market Attractiveness by End-User, 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
